Company news

AstraZeneca PLC news in 2017

AstraZeneca PLC's news releases, calls and decks from 2017, newest first.

View company

FDA accepts Tagrisso submission for 1st-line nsclc

December 18, 2017

EMA accepts Tagrisso submission for 1st-line nsclc

November 28, 2017

AZ submits Tagrisso in Japan for 1st-line nsclc

November 27, 2017

AZ Fasenra receives FDA approval for severe asthma

November 15, 2017

Benralizumab positive CHMP in eosinophilic asthma

November 10, 2017

AZN: Year-To-Date and Q3 2017 Results Announcement

November 9, 2017

AstraZeneca and Aspen complete anaesthetics deal

November 1, 2017

AstraZeneca tralokinumab update in severe asthma

November 1, 2017

US FDA approves AstraZeneca's Calquence for MCL

October 31, 2017

AZ and MSD rapidly advance Lynparza in Japan

October 23, 2017

US FDA approves Bydureon BCise for type-2 diabetes

October 23, 2017

FDA Priority Review for Lynparza in breast cancer

October 18, 2017

FDA accepts sBLA file for Imfinzi; priority review

October 17, 2017

FDA grants Tagrisso BTD for 1st-line EGFR nsclc

October 9, 2017

Aspen acquires remaining rights to AZ anaesthetics

September 14, 2017

Tagrisso potential standard of care in lung cancer

September 11, 2017

IMFINZI superior PFS in Stage III lung cancer

September 11, 2017

Celgene and AZ update on Fusion trial programme

September 7, 2017

AZ tezepelumab cuts exacerbations in severe asthma

September 7, 2017

AZ Duaklir improves lung function in COPD patients

September 7, 2017

Faslodex gets US FDA OK for expanded use in breast

August 29, 2017

Lynparza gets broad FDA approval in ovarian cancer

August 18, 2017

AZ acalabrutinib submission accepted by US FDA

August 2, 2017

BTD for AZ's acalabrutinib in mantle cell lymphoma

August 1, 2017

Imfinzi granted BTD by US FDA for Stage III nsclc

July 31, 2017

Tagrisso significantly improves FLAURA

July 27, 2017

AZ reports initial results from MYSTIC lung trial

July 27, 2017

Az & Merck establish strategic Oncology deal

July 27, 2017

AstraZeneca PLC - H1 2017 Results

July 27, 2017

Faslodex receives EU approval for 1L breast cancer

July 26, 2017

Az completes zomig divestment with Grünenthal

July 3, 2017

Az completes seloken agreement with Recordati

July 3, 2017

Faslodex CHMP positive opinion in 1L breast cancer

June 23, 2017

AZ agreement with Grünenthal for rights to Zomig

June 7, 2017

AstraZeneca prices a $2BN bond issue

June 6, 2017

Lynparza: significant PFS in brcam breast cancer

June 5, 2017

Bydureon EXSCEL trial meets T2D safety objective

May 23, 2017

Az agreement with Recordati for Seloken in Europe

May 22, 2017

Imfinzi significant PFS - unresectable lung cancer

May 12, 2017

AZ updates on tralokinumab trial in severe asthma

May 10, 2017

Durvalumab receives US FDA accelerated approval

May 2, 2017

AstraZeneca: Q1 2017 Results

April 27, 2017

Tagrisso receives full approval in the EU

April 25, 2017

Tagrisso (osimertinib) receives FDA full approval

March 31, 2017

Az completes agreement with TerSera therapeutics

March 31, 2017

US FDA issues CRL for ZS-9 in hyperkalaemia

March 17, 2017

Lynparza PFS in BRCA ovarian maintenance therapy

March 15, 2017

Alliance with Sanofi Pasteur for MEDI8897

March 3, 2017

FDA approves once-daily Qtern for type-2 diabetes

February 28, 2017

CHMP positive opinion for ZS-9 in hyperkalaemia

February 24, 2017

Older news releases →

Decks in 2017